MARKET

IRON

IRON

Disc Medicine Inc
NASDAQ
90.44
+2.95
+3.37%
Pre Market: 92.00 +1.56 +1.72% 08:37 12/19 EST
OPEN
88.00
PREV CLOSE
87.49
HIGH
90.92
LOW
88.00
VOLUME
7.09K
TURNOVER
0
52 WEEK HIGH
99.50
52 WEEK LOW
30.82
MARKET CAP
3.41B
P/E (TTM)
-16.8924
1D
5D
1M
3M
1Y
5Y
1D
Disc Medicine Insider Transaction Raises Eyebrows on Wall Street
TipRanks · 14h ago
Director Kevin Bitterman Reports Disposal of Disc Medicine Inc. i Common Shares
Reuters · 17h ago
Disc Medicine Director Kevin Bitterman Reports Disposal of Common Shares
Reuters · 2d ago
Disc Medicine Chief Medical Officer William Jacob Savage Sells Common Shares
Reuters · 2d ago
Disc Medicine Price Target Raised to $109.00/Share From $91.00 by Wells Fargo
Dow Jones · 3d ago
Disc Medicine Is Maintained at Overweight by Wells Fargo
Dow Jones · 3d ago
Wells Fargo Maintains Overweight on Disc Medicine, Raises Price Target to $109
Benzinga · 3d ago
Analysts Offer Insights on Healthcare Companies: SI-Bone (SIBN), Disc Medicine (IRON) and Novan (NOVN)
TipRanks · 3d ago
More
About IRON
Disc Medicine, Inc. is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The Company's pipeline includes bitopertin for the treatment of erythropoietic porphyrias (Eps), including erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF), and anemia of chronic kidney disease (CKD), and DISC-3405 (formerly MWTX-003) for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, its preclinical programs also include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Bitopertin is the lead product candidate in the Company's heme biosynthesis modulation portfolio. It is developing DISC-3405, a monoclonal antibody against Transmembrane Serine Protease 6 that it licensed from Mabwell Therapeutics, Inc.

Webull offers Disc Medicine Inc stock information, including NASDAQ: IRON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IRON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IRON stock methods without spending real money on the virtual paper trading platform.